The majority of a small group of coronavirus patients showed their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc. (GILD), according to a study published in the The New England Journal of Medicine.The study is based on results from a cohort analysis of 53 patients hospitalized with severe COVID-19 symptoms in the U.S. and around the world, who were treated with the investigational antiviral remdesivir on an individual compassionate use basis. About two-thirds of the patients showed improvement in oxygen support and 17 of 30 of those treated who were on ventilators were …read more
Source:: Yahoo Finance
